[go: up one dir, main page]

PL2234595T3 - Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania - Google Patents

Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania

Info

Publication number
PL2234595T3
PL2234595T3 PL08859423T PL08859423T PL2234595T3 PL 2234595 T3 PL2234595 T3 PL 2234595T3 PL 08859423 T PL08859423 T PL 08859423T PL 08859423 T PL08859423 T PL 08859423T PL 2234595 T3 PL2234595 T3 PL 2234595T3
Authority
PL
Poland
Prior art keywords
glycopyyronium
aggegate
tendency
salt
reducing
Prior art date
Application number
PL08859423T
Other languages
English (en)
Inventor
Gerhard Muhrer
Norbert Rasenack
Michael Juhnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39472711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2234595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2234595T3 publication Critical patent/PL2234595T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08859423T 2007-12-13 2008-12-11 Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania PL2234595T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123164 2007-12-13
PCT/EP2008/067359 WO2009074662A2 (en) 2007-12-13 2008-12-11 Organic compounds
EP08859423A EP2234595B1 (en) 2007-12-13 2008-12-11 Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.

Publications (1)

Publication Number Publication Date
PL2234595T3 true PL2234595T3 (pl) 2013-04-30

Family

ID=39472711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08859423T PL2234595T3 (pl) 2007-12-13 2008-12-11 Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania

Country Status (13)

Country Link
US (1) US20100247658A1 (pl)
EP (1) EP2234595B1 (pl)
JP (1) JP2011506399A (pl)
KR (1) KR20100099281A (pl)
CN (1) CN101896162B (pl)
AU (1) AU2008334543B2 (pl)
BR (1) BRPI0821186A2 (pl)
CA (1) CA2708083C (pl)
ES (1) ES2396471T3 (pl)
PL (1) PL2234595T3 (pl)
PT (1) PT2234595E (pl)
RU (1) RU2482838C2 (pl)
WO (1) WO2009074662A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
CN106604720B (zh) 2014-09-09 2020-03-10 维克多瑞有限公司 包含格隆铵的制剂、方法和设备
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
PT3490533T (pt) * 2016-07-29 2020-07-21 Inke Sa Processo de estabilização do tamanho de partícula
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US8048451B2 (en) * 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
US20060210625A1 (en) * 2003-11-04 2006-09-21 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006073154A1 (ja) * 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. 医薬組成物及びその製造方法
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CN101896162B (zh) 2013-06-05
AU2008334543A1 (en) 2009-06-18
CA2708083C (en) 2016-06-28
KR20100099281A (ko) 2010-09-10
WO2009074662A2 (en) 2009-06-18
CN101896162A (zh) 2010-11-24
US20100247658A1 (en) 2010-09-30
EP2234595A2 (en) 2010-10-06
WO2009074662A3 (en) 2009-09-24
PT2234595E (pt) 2013-01-24
ES2396471T3 (es) 2013-02-21
AU2008334543B2 (en) 2011-07-28
CA2708083A1 (en) 2009-06-18
BRPI0821186A2 (pt) 2015-06-16
EP2234595B1 (en) 2012-11-28
RU2482838C2 (ru) 2013-05-27
RU2010128246A (ru) 2012-01-20
JP2011506399A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
AP2577A (en) Process for preparing diaminophenothiazinium compounds
ZA201104425B (en) A method for the production of pellets or briquettes
TWI371277B (en) Salt form
EP2269483A4 (en) CONTAINING CONTAINER OF THE TYPE TO COGNER
HK1200545A1 (en) Process cartridge
ZA201401797B (en) Fungicidal substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl ]-2-alkoxy-2-cyclyl-ethyl}-1h [1,2,4]triazole compounds
IL199124A (en) A process for preparing fluoromethyl-converted heterocyclic compounds
IL206390A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
EP2181553A4 (en) METHOD FOR UICC TO MANAGE PDP CONTEXT PARAMETERS
ZA201200890B (en) 5,6-bicylic heteroaryl-containing urea compounds as kinase inhibitors
EP2123631A4 (en) PROCESS FOR PRODUCTION OF -ALCOXYPROPIONAMIDE
HRP20160726T1 (hr) Soli piperazina i postupak za njihovu pripravu
PL2234595T3 (pl) Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania
IL207408A0 (en) Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates
IL201670A0 (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
GB0811007D0 (en) Process for makign crystals
ZA201003678B (en) Methods for salt production
PT2143429E (pt) Utilização de cilastatina para reduzir a nefrotoxicidade de diferentes compostos
EP2289875A4 (en) PROCESS FOR PRODUCING PERFLUOROALCANESULFINIC ACID SALT
EP2143718A4 (en) PROCESS FOR PRODUCING TETRAGLYCIDYLAMINO COMPOUND
EP2016066A4 (en) PROCESS FOR PREPARING DULOXETINE
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
IL209462A0 (en) Opiorphin for use as a psychotimulant agent
GB0719218D0 (en) Process tank
IL207190A0 (en) A process for the ultrapurification of alginates